- State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease
The ASNR Standards and Guidelines Committee reviewed new research evidence on GBCA safety and its relevance to current MRI contrast administration guidelines for patients with CKD. The recommendations for CKD patients are that there is no longer a need to withhold group II GBCAs when medically indicated for diagnosis and that it is not necessary to check renal function for these agents.
- Gadolinium-Enhanced T2 FLAIR Is an Imaging Biomarker of Radiation Necrosis and Tumor Progression in Patients with Brain Metastases
Distinguishing radiation necrosis from tumor progression after radiation therapy for brain metastases is challenging on conventional MRI. This study demonstrated higher normalized contrast-enhanced T1 and T2 FLAIR signal intensity for RN. Contrast-enhanced T2 FLAIR signal intensity distinguished RN and TP with an AUC similar to that of DSC perfusion.
AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates